Health Condition 1: B509- Plasmodium falciparum malaria, unspecified
Conditions
Interventions
Intervention1: Arteether Injection: One injection once daily for atleast three days
Control Intervention1: NIL: NIL
Sponsors
Lincoln Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Written informed consent from the patient. 2.Male and Female patients with aged 18 years above inclusive. 3. Diagnosis of Patients with P. falciparum malaria by the presence of ring forms of P. falciparum in thick and thin peripheral blood smears (parasitemia > 5%).
Exclusion criteria
Exclusion criteria: 1. Patients with any condition which in the opinion of the investigator makes the patient unsuitable for inclusion. 2. Patient is a female who is pregnant or willing to get pregnant, not ready to use contraceptive measures during the trial period or breast feeding. 3. Known hypersensitivity to alpha,beta-arteether. 4. Patient with renal failure and other systemic disorder. 5. Patient who is consuming/ has received drugs, which have interaction with alpha,beta-arteether, during last 14 days. 6. Participation in any other clinical trial during last 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean Cure rateTimepoint: after 3 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Parasite clearance timeTimepoint: Based on blood smear test after drug administration of 24 hours, 48 hours and 72 hours | — |
Countries
India
Contacts
Public ContactDr Milan Satia
Ethicare Clinical Trial Services
Outcome results
None listed